• The Evaluation of Health-Related Quality of Life Issues Experienced by Patients with Desmoid-Type Fibromatosis (The QUALIFIED Study)-A Protocol for an International Cohort Study. 

  Schut, A-RW; Timbergen, MJM; Lidington, E; Grünhagen, DJ; van der Graaf, WTA; Sleijfer, S; van Houdt, WJ; Bonenkamp, JJ; Younger, E; Dunlop, A; Jones, RL; Verhoef, C; Gennatas, S; Husson, O (2021-06-22)

  Sporadic desmoid-type fibromatosis (DTF) is a rare soft tissue tumour with an unpredictable clinical course. These tumours are incapable of metastasising, but their local aggressive tumour growth and tendency to recur ...
• Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. 

  Sartor, O; de Bono, J; Chi, KN; Fizazi, K; Herrmann, K; Rahbar, K; Tagawa, ST; Nordquist, LT; Vaishampayan, N; El-Haddad, G; Park, CH; Beer, TM; Armour, A; Pérez-Contreras, WJ; DeSilvio, M; Kpamegan, E; Gericke, G; Messmann, RA; Morris, MJ; Krause, BJ; VISION Investigators (2021-06-23)

  <h4>Background</h4>Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. ...
• Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium. 

  Shern, JF; Selfe, J; Izquierdo, E; Patidar, R; Chou, H-C; Song, YK; Yohe, ME; Sindiri, S; Wei, J; Wen, X; Rudzinski, ER; Barkauskas, DA; Lo, T; Hall, D; Linardic, CM; Hughes, D; Jamal, S; Jenney, M; Chisholm, J; Brown, R; Jones, K; Hicks, B; Angelini, P; George, S; Chesler, L; Hubank, M; Kelsey, A; Gatz, SA; Skapek, SX; Hawkins, DS; Shipley, JM; Khan, J

  <h4>Purpose</h4>Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood. Despite aggressive therapy, the 5-year survival rate for patients with metastatic or recurrent disease remains poor, and beyond ...
• ATARI trial: ATR inhibitor in combination with olaparib in gynaecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI) 

  Bliss, J; Porta, N; Toms, C; Banerjee, S; Stewart, J; Natrajan, R; Lord, C
• Improving outcomes for the lung cancer patient with impaired lung function 

  Walder, D (2021-03-31)

  Lung function impairment is common amongst patients with lung cancers. Identifying the patients that are most likely to benefit from anti-cancers therapies, without suffering significant toxicities, is central to improving ...
• Study protocol for a randomised controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials (CONSENT) 

  Pal, A; Stapleton, S; Yap, C; Lai-Kwon, J; Daly, R; Magkos, D; Baikady, BR; Minchom, A; Banerji, U; De Bono, J; Karikios, D; Boyle, F; Lopez, J

  <jats:sec><jats:title>Introduction</jats:title><jats:p>Early phase cancer clinical trials have become increasingly complicated in terms of patient selection and trial procedures—this is reflected in the increasing length ...
• Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. 

  Early Breast Cancer Trialists’ Collaborative group (EBCTCG)

  <h4>Background</h4>Trastuzumab targets the extracellular domain of the HER2 protein. Adding trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer reduces the risk of recurrence and death, ...
• Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler 

  Bergholtz, H; Carter, JM; Cesano, A; Cheang, MCU; Church, SE; Divakar, P; Fuhrman, CA; Goel, S; Gong, J; Guerriero, JL; Hoang, ML; Hwang, ES; Kuasne, H; Lee, J; Liang, Y; Mittendorf, EA; Perez, J; Prat, A; Pusztai, L; Reeves, JW; Riazalhosseini, Y; Richer, JK; Sahin, Ö; Sato, H; Schlam, I; Sørlie, T; Stover, DG; Swain, SM; Swarbrick, A; Thompson, EA; Tolaney, SM; Warren, SE

  <jats:p>Breast cancer is a heterogenous disease with variability in tumor cells and in the surrounding tumor microenvironment (TME). Understanding the molecular diversity in breast cancer is critical for improving prediction ...
• Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA. 

  Sumanasuriya, S; Seed, G; Parr, H; Christova, R; Pope, L; Bertan, C; Bianchini, D; Rescigno, P; Figueiredo, I; Goodall, J; Fowler, G; Flohr, P; Mehra, N; Neeb, A; Rekowski, J; Eisenberger, M; Sartor, O; Oudard, S; Geffriaud-Ricouard, C; Ozatilgan, A; Chadjaa, M; Macé, S; Lord, C; Baxter, J; Pettitt, S; Lambros, M; Sharp, A; Mateo, J; Carreira, S; Yuan, W; de Bono, JS

  <h4>Background</h4>Better blood tests to elucidate the behaviour of metastatic castration-resistant prostate cancer (mCRPC) are urgently needed to drive therapeutic decisions. Plasma cell-free DNA (cfDNA) comprises normal ...
• Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. 

  Sternberg, CN; Castellano, D; de Bono, J; Fizazi, K; Tombal, B; Wülfing, C; Kramer, G; Eymard, J-C; Bamias, A; Carles, J; Iacovelli, R; Melichar, B; Sverrisdóttir, Á; Theodore, C; Feyerabend, S; Helissey, C; Poole, EM; Ozatilgan, A; Geffriaud-Ricouard, C; de Wit, R (2021-07-14)

  <h4>Background</h4>In the CARD study (NCT02485691), cabazitaxel significantly improved median radiographic progression-free survival (rPFS) and overall survival (OS) versus abiraterone/enzalutamide in patients with metastatic ...
• Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies. 

  Roulstone, V; Mansfield, D; Harris, RJ; Twigger, K; White, C; de Bono, J; Spicer, J; Karagiannis, SN; Vile, R; Pandha, H; Melcher, A; Harrington, K

  <h4>Background</h4>Oncolytic reovirus therapy for cancer induces a typical antiviral response to this RNA virus, including neutralizing antibodies. Concomitant treatment with cytotoxic chemotherapies has been hypothesized ...
• Frequency and Prognostic Impact of <i>ALK</i> Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). 

  Bellini, A; Pötschger, U; Bernard, V; Lapouble, E; Baulande, S; Ambros, PF; Auger, N; Beiske, K; Bernkopf, M; Betts, DR; Bhalshankar, J; Bown, N; de Preter, K; Clément, N; Combaret, V; Font de Mora, J; George, SL; Jiménez, I; Jeison, M; Marques, B; Martinsson, T; Mazzocco, K; Morini, M; Mühlethaler-Mottet, A; Noguera, R; Pierron, G; Rossing, M; Taschner-Mandl, S; Van Roy, N; Vicha, A; Chesler, L; Balwierz, W; Castel, V; Elliott, M; Kogner, P; Laureys, G; Luksch, R; Malis, J; Popovic-Beck, M; Ash, S; Delattre, O; Valteau-Couanet, D; Tweddle, DA; Ladenstein, R; Schleiermacher, G (2021-06-11)

  <h4>Purpose</h4>In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated through activating point mutations or genomic amplification. We studied <i>ALK</i> genetic alterations in high-risk ...
• A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF(V600) wild-type colorectal cancer 

  Georgiou, A; Stewart, A; Vlachogiannis, G; Pickard, L; Valeri, N; Cunningham, D; Whittaker, SR; Banerji, U (SPRINGER, 2021-08-30)
• Precision genomics for prostate cancer patient stratification 

  Seed, G (2020-10-31)

  Introduction Several unmet needs currently persist in advanced prostate cancers. Despite recent discoveries, such as identification of deficient DNA repair pathways as a key driver of prostate tumour development, relatively ...
• Biological Role of MYCN in Medulloblastoma: Novel Therapeutic Opportunities and Challenges Ahead. 

  Shrestha, S; Morcavallo, A; Gorrini, C; Chesler, L

  The constitutive and dysregulated expression of the transcription factor MYCN has a central role in the pathogenesis of the paediatric brain tumour medulloblastoma, with an increased expression of this oncogene correlating ...
• Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis. 

  Herranz, C; Mateo, F; Baiges, A; Ruiz de Garibay, G; Junza, A; Johnson, SR; Miller, S; García, N; Capellades, J; Gómez, A; Vidal, A; Palomero, L; Espín, R; Extremera, AI; Blommaert, E; Revilla-López, E; Saez, B; Gómez-Ollés, S; Ancochea, J; Valenzuela, C; Alonso, T; Ussetti, P; Laporta, R; Xaubet, A; Rodríguez-Portal, JA; Montes-Worboys, A; Machahua, C; Bordas, J; Menendez, JA; Cruzado, JM; Guiteras, R; Bontoux, C; La Motta, C; Noguera-Castells, A; Mancino, M; Lastra, E; Rigo-Bonnin, R; Perales, JC; Viñals, F; Lahiguera, A; Zhang, X; Cuadras, D; van Moorsel, CHM; van der Vis, JJ; Quanjel, MJR; Filippakis, H; Hakem, R; Gorrini, C; Ferrer, M; Ugun-Klusek, A; Billett, E; Radzikowska, E; Casanova, Á; Molina-Molina, M; Roman, A; Yanes, O; Pujana, MA (2021-08-11)

  Inhibition of mTOR is the standard of care for lymphangioleiomyomatosis (LAM). However, this therapy has variable tolerability and some patients show progressive decline of lung function despite treatment. LAM diagnosis ...
• What Matters to Us: Impact of Telemedicine During the Pandemic in the Care of Patients With Sarcoma Across Scotland. 

  McCabe, HM; Smrke, A; Cowie, F; White, J; Chong, P; Lo, S; Mahendra, A; Gupta, S; Ferguson, M; Boddie, D; Mmekka, W; Stirling, L; Campbell, L; Jones, RL; Nixon, I

  <h4>Purpose</h4>In Scotland, approximately 350 sarcoma cases are diagnosed per year and treated in one of the five specialist centers. Many patients are required to travel long distances to access specialist care. The ...
• Post Hoc Health-Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies. 

  Thiery-Vuillemin, A; Fizazi, K; Sartor, O; Oudard, S; Bury, D; Ozatilgan, A; Poole, EM; Eisenberger, M; de Bono, J

  <h4>Background</h4>The phase III PROSELICA (NCT01308580) and FIRSTANA (NCT01308567) trials investigated taxane chemotherapy among men with postdocetaxel metastatic, castration-resistant prostate cancer (mCRPC) or ...
• The PTEN and ATM axis controls the G1/S cell cycle checkpoint and tumorigenesis in HER2-positive breast cancer. 

  Bassi, C; Fortin, J; Snow, BE; Wakeham, A; Ho, J; Haight, J; You-Ten, A; Cianci, E; Buckler, L; Gorrini, C; Stambolic, V; Mak, TW (2021-05-31)

  The tumor suppressor PTEN is disrupted in a large proportion of cancers, including in HER2-positive breast cancer, where its loss is associated with resistance to therapy. Upon genotoxic stress, ataxia telangiectasia mutated ...
• Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications 

  Sheehan, B; Guo, C; Neeb, A; Paschalis, A; Sandhu, S; de Bono, JS

View more